As Cdk Global INC (CDK) Shares Declined, Senator Investment Group LP Increased Its Stake by $58.83 Million

CDK Global, Inc. (NASDAQ:CDK) Corporate Logo

In Cdk Global Inc (CDK) was rose the stake owned by Senator Investment Group Lp. The reduction is 43.1% according to 2018Q2 SEC form. 905,000 shares were bought by Senator Investment Group Lp as the company’s stock declined 5.06% while stock markets rallied. The miscellaneous company announced $195.48 million value for the 2018Q2. Now the hedge fund is holding 3.01 million shares, compared to the 2.10 million from the previous quarter. $6.18B is Cdk Global Inc’s market cap. CDK is hitting $47.98 during the last trading session, after decreased 2.54%.CDK Global, Inc. has volume of 912,523 shares. Since December 8, 2017 CDK has risen 1.03% and is uptrending. CDK underperformed the S&P500 by 14.59%.

About $11.90 billion and $10.06B US Long portfolio Senator Investment Group Lp operates. It decreased its stake in Jazz Pharmaceuticals Plc (NASDAQ:JAZZ) by 468,295 shares to 1.03M shares, valued at $177.47 million in 2018Q2, according to the filing. For a total of 2.27M shares it reduced its holding in Fgl Hldgs by 4.25 million shares in the quarter, and has cut its stake in Facebook Inc (NASDAQ:FB).

For more CDK Global, Inc. (NASDAQ:CDK) news brought out recently go to: Nasdaq.com, Nasdaq.com, Nasdaq.com, Nasdaq.com or Nasdaq.com. The titles are as follows: “Ex-Dividend Reminder: Stifel Financial, Jack Henry & Associates and CDK Global – Nasdaq” brought out on November 28, 2018, “CDK Global Enters Oversold Territory – Nasdaq” on October 08, 2018, “CDK Global Announces Entry into an Accelerated Share Repurchase Agreement to Repurchase $260 Million of its Common Stock – Nasdaq” with a publish date: November 09, 2018, “Radius Health Provides Updates on its Oncology Programs and Announces Scientific Presentations at 2018 San Antonio Breast Cancer Symposium (SABCS) – Nasdaq” and the last “Immunomedics Provides Clinical Updates on Breast Cancer Programs With Sacituzumab Govitecan – Nasdaq” with publication date: December 06, 2018.

CDK Global, Inc. (NASDAQ:CDK) Ratings Coverage

In total 2 analysts cover CDK Global (NASDAQ:CDK). “Buy” rating has 0, “Sell” are 0, while 2 are “Hold”. (NASDAQ:CDK) has 0 bullish analysts. 2 are the (NASDAQ:CDK)’s ratings reports on 8 Dec 2018 according to StockzIntelligence Inc. On Wednesday, August 15 the stock has “Equal-Weight” rating by Morgan Stanley. In Thursday, November 8 report Wells Fargo downgraded the stock to “Market Perform” rating.

CDK Global, Inc. (NASDAQ:CDK) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.